Scientific Publications & Case Reports 

Collection of peer reviewed case reports and studies citing adverse effects post COVID vaccination.

Researching Covid vaccine adverse events can be daunting in part due to a broad myriad of factors. Primarily, the information is incredibly challenging to find. Here, we share an ever growing list of peer-reviewed studies specific to Covid vaccine adverse events. This list is curated and maintained by our dedicated staff of injured PhDs and medical professionals.

Before diving in, please take a look at our Research Primer: How to Read and Understand Research for tools to how best approach the massive amount of information found in the document below. As always, this is for informational purposes only. Please discuss with your trusted medical team.

Are we missing a few? Please email us and let us know.
Printable Version 2.1



Updated: 7/25/2022 – Added POTS, Tinnitus, and Other; 7/3/2022 – Added 250 Neuro, Cardiac, and MIS-V 

1250+ Peer-Reviewed Publications:

NeurologicPulmonary | Cardiovascular | Gastrointestinal | Renal | Oncology | Ophthalmology | Ear Nose and Throat | Autoimmune | MIS-V | OBGYN | Miscellaneous




Spectrum of neurological complications following COVID-19 vaccination:

COVID-19 mRNA vaccination leading to CNS inflammation: a case series

A systematic review of cases of CNS demyelination following COVID-19 vaccination:

Spectrum of neuroimaging findings in post-covid-19 vaccination: a case series and review of the literature:

Neurologic autoimmune diseases following vaccinations:

New-onset autoimmune phenomena post COVID-19 vaccination:

Neurologic side effects of COVID-19 vaccinations:

Rebuttal about Functional Neurologic Disorders and Vaccination:

Neurologic safety monitoring of COVID-19 vaccines, lessons learned from the past to inform the present:

Neurological side effects after first dose AstraZeneca and COVID-19 infection:

Covid Vaccines are not free of Neurologic side effects:

Combined central and peripheral demyelination with Anti-neurofascin155 IgG following AstraZeneca:

Intracranial aneurysm rupture within 3 days of receiving mRNA vaccination: 3 case reports:

Cerebrovascular complications of COVID-19 and COVID-19 vaccination:



 Small fiber neuropathy and POTS following Moderna and Pfizer vaccination (NIH publication):

Small fiber neuropathy:

COVID-19 vaccinations may not only be complicated by GBS but also by distal small fiber neuropathy:

Possible mechanisms of neuropathies associated with covid-19 vaccination:

Acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analysis in VigiBase:

Polyneuropathy in a 43yoF following Pfizer:

Recrudescence of severe polyneuropathy after receiving Pfizer vaccine in a patient with a history of eosinophilic granulomatosis with polyangiitis:


POTS (Postural Orthostatic Tachycardia Syndrome):

(See NIH Publication in neuropathy section above)

Postural orthostatic tachycardia syndrome after mRNA COVID-19 vaccine:  

POTS following Pfizer:

Autonomic dysfunction post-inoculation with ChAdOx1 nCoV-19 vaccine



Neuralgia – Trigeminal, Amytrophy: Trigeminal neuritis after Pfizer:

Trigeminal Neuralgia and cervical radiculitis after Pfizer:

Neuralgic amyotrophy following mRNA vaccination:

Amyotrophic neuralgia secondary to AstraZeneca:

Neuralgic amyotrophy of the lumbosacral plexus following AstraZeneca:

Parsonage-Turner syndrome following Pfizer:

Parsonage-Turner syndrome in a 43yoM after COVID-19 vaccination:

2 cases of Parsonage Turner Syndrome following Moderna and Pfizer:

Parsonage—Turner syndrome following Astra Zeneca: a case report and review of the literature:


Transverse Myelitis:

36yoM with transverse myelitis following AstraZeneca:

Acute Myelitis following AstraZeneca:

67yoF with transverse myelitis following Moderna 1st dose:

70yoM with acute autoimmune transverse myelitis following Moderna:

Longitudinal extensive transverse myelitis following AstraZeneca:

Longitudinal extensive transverse myelitis in a 25yoF following AstraZeneca:

Longitudinal extensive transverse myelitis following AstraZeneca:

Acute transverse myelitis following AstraZeneca:

Transverse Myelitis and Bells Palsy after J&J vaccination:

Acute transverse myelitis in 43 patients post AstraZeneca Vaccination:

MOG-antibody associated longitudinal extensive myelitis after AstraZeneca in a 59yoM:

MOG antibody associated disease (38yoM) and transverse myelitis (39yoF) following Pfizer:


GBS (Guillain Barre Syndrome):

12 cases of GBS and 4 cases of CIDP following COVID-19 vaccination in the UK:

24 cases of GBS following COVID-19 vaccination:

Sensory GBS in a 16yoF following Pfizer:

Sensory ataxic GBS with immunoglobulin G anti-GM1 antibodies following Pfizer:

AstraZeneca and GBS: analysis using National Immunoglobulin Database:

GBS following Johnson and Johnson:

GBS following 2nd dose of Pfizer:, electromyoneurography and laboratory findings:

 3 cases of GBS in Alberta following AstraZeneca:

GBS in a 23yoM following Pfizer:

Sensory ataxic GBS in a 80yoM following Pfizer:

GBS in a 58yoF with rapid onset and autonomic dysfunction following 1st dose Pfizer:

GBS in a 80yoM following Moderna:

GBS in a 25yoF following 2nd dose of Pfizer:

GBS following Pfizer in a 42yoM :

GBS in a 42yoF following Pfizer:

GBS in a 61yoM following Moderna:

GBS in a 65yoM liver transplant patient following Pfizer:

GBS in a 67yoM following 1st dose of Pfizer:

GBS in a 73yoM following Moderna:

GBS in 73yoM following 2nd dose of Pfizer:

GBS in 82yoF following 1st dose Pfizer:

GBS 10 days after AstraZeneca:

GBS 11 days after AstraZeneca:

GBS following AstraZeneca with papilledema as atypical onset:

GBS following AstraZeneca:

GBS in a 63yo patient who had previous vaccine associated GBS syndrome following AstraZeneca:

Recurrent GBS following mRNA vaccination:

3 cases of GBS following AstraZeneca:

3 cases of GBS and 1 case of CIDP following AstraZeneca in Tasmania:

7 cases of GBS following AstraZeneca:

19 cases of GBS following J&J, Pfizer, and Astra Zeneca vaccination:

GBS following vaccination, a review of 39 cases:

2 cases of Sensory GBS following AstraZeneca:

Bilateral facial weakness with paresthesia variant of GBS following AstraZeneca:

Bifacial diplegia variant of GBS following J&J vaccination:

GBS presenting as bifacial diplegia in 2 patients following AstraZeneca:

 GBS following Johnson and Johnson:

GBS following Moderna:

GBS following 1st dose AstraZeneca: 

GBS with Prominent Facial Diplegia after AstraZeneca:

GBS in a 14yoM following Pfizer:

GBS in a 21yoM following Pfizer:

GBS in a 38yoF following AstraZeneca:

GBS in a 49yoF following AstraZeneca:

2 cases of GBS following Pfizer in patients in remission from b-cell lymphoma:

2 cases of GBS after Pfizer and AstraZeneca:

GBS following COVID-10 vaccination: a report of 2 cases:

Facial Diplegia variant of GBS in a 38yoM following COVID-19 vaccination:

Facial Diplegia variant of GBS in a 65yoF following J&J:

Axonal-variant GBS in 86yoF temporally associated with Moderna vaccination:


Miller Fisher Syndrome:

Miller Fischer syndrome and GBS overlap syndrome after AstraZeneca:

Miller Fisher syndrome in 24yoF following Pfizer:

Miller Fisher Syndrome in a 71yoM following Pfizer:

Miller Fisher syndrome after 2nd dose of Pfizer vaccination in a patient with resolved covid-19



75yoF with acute hemorrhagic necrotizing encephalopathy after AstraZeneca:

32yoM with acute hyperactive encephalopathy after Moderna with dramatic response to methylprednisolone:

Facial Weakness, extremity weakness, encephalopathy, and severe refractory ITP following Moderna:

77yoM with acute encephalopathy and NSTEMI following Moderna:



Chronic inflammatory demyelinating polyneuropathy after following Moderna:

CIPD in a middle aged female following Moderna:

Acute onset chronic inflammatory demyelinating polyneuropathy (CIDP) after AstraZeneca:

Chronic inflammatory demyelinating polyneuropathy after AstraZeneca vaccination:



Transient akathisia after Pfizer:





Bells Palsy / Nerve Palsy:

Multiple cranial nerve palsies following COVID-19 vaccination (Pfizer):

Acute abducens nerve palsy following Pfizer:

Acute aducens nerve palsy following AstraZeneca:

Acute Abducens nerve palsy following vaccination:

21yoF nurse with Bells Palsy following Pfizer:

34yoF with Bells Palsy 2 days after Moderna:

36yo with Bells Palsy, left arm tingling/numbness/weakness following mRNA vaccination:

32yoF with Bells Palsy following Pfizer:

37yoM with Bells Palsy after Pfizer:

50yoM with Bells Palsy after Pfizer, ongoing symptoms after 21 days:

57yoF with Bells Palsy <36 hours after 2nd dose of Pfizer:

61yoM with Bells Palsy after each dose of Pfizer:

Bells Palsy following mRNA and inactivated (CoronaVac) vaccines: a case series and nested case-control study:

Rate of Bells Palsy following mRNA vaccination is 2-3x higher then expected:


Neuromyelitis Optica:

New onset neuromyelitis optica spectrum disorder following Pfizer:

Neuromyelitis optic in a healthy female following Moderna:

Neuromyelitis optica spectrum disorder (NMOSD):

Antibody positive neuromyelitis optica spectrum disorder after 2nd dose Pfizer in a 80yoM:

Optic neuropathy after Pfizer and Astrazeneca: a report of 2 cases:

Bilateral optic neuritis after AstraZeneca:

Optic neuritis and transverse myelitis in MS patient after Astrazeneca vaccination:


Multiple Sclerosis:

Patient’s first MS Flare following Pfizer

New onset MS in a 32yoF patient following Pfizer:

New onset of MS in a 40yoF following Pfizer:

3 new cases of MS, 13 flares of MS after Pfizer, Moderna, and Astra Zeneca vaccination:

4 cases of activation of stable MS, 2 cases of new MS, 1 case of new onset neuromyelitis optica after mRNA vaccination:

COVID infection and vaccination outcomes in multiple sclerosis:

Severe Multiple Sclerosis relapse after Pfizer:

5 cases of new diagnosis of multiple sclerosis following mRNA vaccination:

Optic neuritis and transverse myelitis in MS patient after Astrazeneca vaccination:


Myasthenia Gravis:

Vaccination associated Ocular Myasthenia Gravis following Pfizer:

Myasthenia Gravis Flare Following Moderna:

Fatal Myasthenic Crisis in a 55yoM following AstraZeneca:

New onset Myasthenia Gravis in 82yoM following Pfizer:


Cerebral Venous Thrombosis:

Thromboembolic events following mRNA COVID vaccination, a case series:

CVA and Thrombocytopenia following Astrazeneca:

Cerebral venous sinus thrombosis after Moderna in a 56yoF:

Extensive cerebral venous sinus thrombosis after 1st dose Pfizer without TTS in a 28yoF:

Cerebral venous thrombosis due to VITT after 2nd dose of AstraZeneca:

Age-stratified risk of cerebral venous sinus thrombosis after AstraZeneca:

Characteristic of outcomes in patients with cerebral venous sinus thrombosis in COVID vaccine induced immune thrombotic thrombocytopenia:

Cerebral venous sinus thrombosis in setting of COVID-19 vaccination: a systematic review and meta-analysis:

US case reports of cerebral venous sinus thrombosis with thrombocytopenia after J&J:

Cerebral venous thrombosis in a 61yoM following Pfizer:

Cerebral venous sinus thrombosis after mRNA vaccination:

Central venous sinus thrombosis with subarachnoid hemorrhage in a 45yoM following Moderna:

Cerebral venous sinus thrombosis after AstraZeneca, neurologic and radiological management:

Cerebral venous sinus thrombosis, subarachnoid hemorrhage, and thrombocytopenia following AstraZeneca:

Cerebral Venous sinus thrombosis, review of European cases:

Review of European data of Cerebral venous thrombosis with cytopenia, observed in Pfizer, Moderna, and AstraZeneca

A multicenter cohort study of cerebral venous thrombosis after AstraZeneca Vaccination:

Endovascular treatment for AstraZeneca induced cerebral venous sinus thrombosis and thrombocytopenia, a report of 3 cases:

45 cases of Cerebral Venous thrombosis:

International Cerebral Venous Thrombosis consortium report on cerebral venous thrombosis following vaccination against SARS-COV-2:

Spontaneous rare visceral pseudoaneurysm presenting with rupture after Moderna:


Intracerebral Hemorage / Strokes / etc:

Fatal ICH following AstraZeneca:

ICH due to vasculitis following Pfizer:

Treatment of AstraZeneca induced immume thrombotic thrombocytopenia related acute ischemic stroke:

Symptomatic penducular, cavernous bleeding following Pfizer vaccination induced ITP:

Lobar bleeding with ventricular rupture shortly following mRNA vaccine:

Bilateral thalamic stroke following Pfizer: a case of VITT?



Aphasia 7 days after 2nd dose of mRNA based vaccine due to intracerebral bleeding in left temporal lobe:



Worsening Neuro-Oncologic Disease Symptoms following mRNA vaccination:


Headache / Aseptic Meningitis:

18yoM with aseptic meningitis following Pfizer:

Aseptic meningitis, mucocutaneous lesions, and arthritis after Pfizer in a 15yoM:

Aseptic meningitis in a 34yoF following Pfizer:

Headache after AstraZeneca: a MultiCenter observational cohort center:

Status migrainosus following Pfizer:

Characteristics of COVID vaccine induced Headache:

Clinical characteristics of Headache following Pfizer, a multicenter observational cohort study:

Aseptic Meningitis following Pfizer:

Aseptic meningitis after Pfizer:

Steroid responsive aseptic meningitis after Pfizer in a 62yoF:


Encephalitis / Delirium:

Delirium in an elderly patient following vaccination:

Two cases of encephalopathy and seizures following Moderna:

Acute meningoencephalitis in a 72yoF after Pfizer:

Acute encephalitis following AstraZeneca:

Anti-LGI1 encephalitis following COVID-19 vaccination: a case series:

69yoF with acute transient encephalopathy following Moderna:

Acute disseminated encephalitis following Pfizer:

Acute disseminated encephalomyelitis (ADEM) following AstraZeneca:

ADEM with bilateral optic neuritis following AstraZeneca:

Acute disseminated encephalomyelitis (ADEM) in a 88yoF following Pfizer vaccination:

COVID-19 Moderna booster induced autoimmune encephalitis in a 48yoM:

Anti-LGI1 encephalitis in a 48yoM following mRNA vaccination:

Autoimmune encephalitis in a 35yoF following AstraZeneca:

Case report of AstraZeneca associated encephalitis in a 22yoF:

Acute Disseminated Encephalitis in a young female following mRNA vaccination:

Postvaccinal encephalitis followingAstraZeneca:

Acute encephalitis, myoclonus, and sweet syndrome after mRNA vaccine:

Acute psychosis due to anti-NMDA encephalitis in a young female in her 20s following Pfizer vaccination:

First episode of psychosis in 18yoF following AstraZeneca:

New onset psychosis in 31yoM after mRNA vaccine:



COVID-19 vaccine associated parkinson’s disease, a prion disease signal in UK yellow card adverse event database:

COVID-19 RNA based vaccines and the risk of prion disease:

Clinical and radiological follow-up of Pfizer induced hemichorea hemiballismus in a 90yoM:

Polyneuritis cranialis, a rare GBS variant, associated with Pfizer in a 16yoF:

Reversible radiculomyelitis after AstraZeneca:

Severe dyskinesia in Parkinson Patient following mRNA vaccination:

Hemichorea following Pfizer:

3 cases of worsening complex regional pain syndrome following mRNA vaccination:

Cytotoxic lesion of the Corpus Callousum following mRNA vaccination:

Myeloperoxidase anti-neutrophil cytoplasmic antibody positive optic perineuritis after mRNA vaccination:

Two patients with schizophrenia treated with clozapine develop neutropenia after COVID-19 vaccine:

Three cases: CVA, left facial nerve palsy, and myelitis all following AstraZeneca:


Vaccine induced interstitial lung disease in 86yoM after mRNA vaccine:

Vaccine induced interstitial lung disease:

Delayed hypersensitivity to Pfizer presenting with pneumonitis and rash:

Pfizer vaccine induced Pneumonitis in a 65yoM:

Interstitial lung disease in a 71yoF after receiving mRNA vaccine:

2 cases (67yoM and 70yoM) of Pfizer related interstitial lung disease:

Pulmonary embolus and DVT in a 14yoM after Pfizer:

2 cases of eosinophilic pneumonia following vaccination:

Interstitial lung disease after COVID-19 vaccination may be more common in Asians:

Acute eosinophilic pneumonia in a 37yo M following Pfizer vaccination:

Acute eosinophilic pneumonia following AstraZeneca vaccination:

Pulmonary Embolus following Moderna: 

2 cases of Pulmonary embolus following AstraZeneca:




Cardiovascular and hematological events post COVID-19 vaccination: a systemic review:

American Heart Association: Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults

American Heart Association: Observational Findings of PULS Cardiac Test Findings for Inflammatory Markers in Patients Receiving mRNA Vaccines

Note the distinction between myocarditis, novel coronavirus myocarditis, and covid-19 vaccine associated myocarditis:

JAMA article, concerns for perimyocarditis underreporting, review of 40 hospitals:

Intravenous injection of mRNA vaccine can induce acute myopericarditis in mouse model:

The Novel platform of mRNA vaccines and myocarditis: clues into the potential underlying mechanism:

Proposed pathogenesis, characteristics, and management of mRNA related myopericarditis:

mRNA and Pericarditis/myocarditis risk compared to other vaccine types:

ACS risk factor biomarkers increase after mRNA vaccination:

A review of cardiac side effects from Pfizer and Moderna in Singapore:

Fatal fulminant necrotizing eosinophilicy myocarditis following 1st dose Pfizer:

Immune mediated necrotizing myopathy after Pfizer:

Severe necrotizing myopathy after Pfizer and regimen of ipulimumab plus nivolumab in a patient with advanced melanoma:


Myocarditis – Pericarditis – Reports:

1077 cases of myocarditis and 1149 pericarditis following vaccination in Nordic residents, a cohort study:

1626 cases of myocarditis in VAERS from Dec 2020-augut 2021, a review (JAMA):

Myocarditis/myopericarditis in 269 individuals, a population based Danish cohort study:

Myocarditis in adolescents and adults following vaccination in 2021, review of 238 cases:

Review of 40 published case reports of myocarditis following covid vaccination:

Myopericarditis recurrence in a 27yoM after 3rd dose Pfizer:

Biopsy proven fulminant myocarditis in a 48yoF following 2nd dose Moderna:

Fulminant myocarditis in a 80yoF following Pfizer:

8 cases of myocarditis after mRNA vaccination:

COVID-19 vaccine, myocardial infarction, and Kounis syndrome:

Myocarditis in a 17yoM following vaccination:

4 cases of myocarditis following Pfizer booster in Israel:

Moderna associated myopericarditis in a patient with a subclinical autoimmune predisposition:

Perimyocarditis in teens:

Vaccination associated myocarditis in Adolescents:

mRNA vaccination and myocarditis in adolescents:

Association of myocarditis with mRNA vaccination, a case review in children:

STEMI mimic: focal myocarditis in an adolescent patient after mRNA COVID-19 vaccine:

Recurrence of myocarditis after vaccination

Acute Myocardial Injury following COVID-19 vaccination: a case report and review of current evidence from VAERS:

Myocarditis in a 27yoM following Pfizer: CMR features:

Myocarditis in a 17yo Japanese male following Moderna:

Myocarditis and/or pericarditis after mRNA vaccination: head to head comparison of Moderna versus Pfizer:

Fulminant myocarditis requiring ECMO in a 60yoF following 2nd dose Pfizer:

Acute pericarditis following mRNA booster:

Myocarditis or pericarditis following mRNA vaccination:

Myocarditis with hemorrhagic pericardial effusion following Pfizer:

Myopericarditis in young adults presenting to the ED:

Pericarditis following mRNA vaccination:

Symptomatic pericarditis following Pfizer:

Myocarditis following J&J in a healthy, young male:

Acute myocarditis after Moderna in young male:

Myocarditis in a healthy male:

Acute myocarditis following vaccination:

Acute myocarditis following Pfizer in a healthy man with previous COVID infection:

Acute fulminant myocarditis following mRNA vaccination requiring ECMO:

Myocarditis case report:

Case report: probable myocarditis after mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy:

Myocarditis following mRNA vaccination:

A late presentation of vaccine induced myocarditis:

Myocarditis in 24yoM:

Myocarditis in a 24yoM nurse after Pfizer:

Myocarditis in a 15yo following Pfizer:

Myopericarditis in a 16yo following vaccination

Myocarditis in a 16yo, late gadolinium enhancement:

Myocarditis in a 22yoM following Moderna:

4 cases of myocarditis after 3rd dose of Pfizer: magnetic resonance imaging study (18-44yo):

5 cases of myocarditis after Pfizer:

7 cases of myocarditis after mRNA vaccination:

Myocarditis presenting with hyperechoic nodule in a 17yoM following Pfizer:

Myocarditis in a 18yoM following Pfizer:

Myocarditis in a middle aged male with significant left ventricular dysfunction following Pfizer:

70yoF with myocarditis following J&J Vaccination:

Biopsy proven lymphocytic myocarditis following 1st mRNA vaccination in a 40yo:

Cardiac imaging of acute myocarditis following mRNA in a 24yoM:

Cardiac MRI findings in young adults following mRNA vaccination: a case series:

Case report: probable myocarditis after mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy:

Myocarditis following mRNA vaccination:

A rare case of myocarditis and pulmonary embolism after Pfizer:

A late presentation of vaccine induced myocarditis:

5 cases of myocarditis after Pfizer (age 16 and up):

Myocarditis in a 13yoM following Pfizer:

Follow-up cardiac magnetic resonance in 7 children with Pfizer vaccine associated myocarditis (80% with persistent abnormalities at 90 days):

7 cases of myocarditis after mRNA vaccination (age 16 and up):

Followup CMR imaging in 15 patients 6 months after Pfizer associated myocarditis (age 14-19):

Follow-up cardiac magnetic resonance (CMR) in 7 children with Pfizer vaccine associated myocarditis:

Followup CMR imaging in 15 patients 6 months after Pfizer associated myocarditis:

2 cases of myocarditis presenting with ST segment elevation in adolescent males after Pfizer:

Cardiac complications following mRNA vaccination: a systematic review of case reports and case series:

Myopericarditis following mRNA vaccination: the role of cardiac biomarkers and multimodality imaging:

Myocarditis should be consider in those with a troponin rise and unobstructed arteries following Pfizer vaccination:

Myocarditis Associated with COVID-19 vaccination: echocardiography, cardiac tomography, and magnetic resonance imaging findings:

Cardiac magnetic resonance characteristics of acute myocarditis occuring after mRNA vaccine immunization:

Fulminant myocarditis and systemic hyperinflammation in 2 patients following mRNA:

2 cases of histological confirmed myocarditis following mRNA vaccination:

Myocarditis and Pericarditis: 2 case reports:

Two cases of myocarditis

3 cases of cardiac manifestation following Pfizer:

4 cases of Myocarditis and their Cardiac MRI findings:

4 cases of myocarditis:

6 cases of men age 17-37 with myocarditis:

8 cases of myocarditis in adolescents following Pfizer:

13 cases of Myocarditis in adolescents following Pfizer:

Review of 15 published cases of myocarditis:

Myocarditis and pericarditis due to mRNA vaccines in 19 cases:

Myocarditis in 23 military members:

Review of 29 published cases of acute myopericarditis following mRNA vaccination:

Review of 214 myocarditis cases::



Covid-19 vaccine associated Takotsubo cardiomyopathy:

63yoF with Takotsubo cardiomyopathy following Moderna:

Reverse takotsubo cardiomyopathy as a cause of acute chest pain in a young woman following COVID-19 vaccination:


Acute MI (Myocardial Infarction):

3 cases of acute infarct-like myocarditis (2 Pfizer, 1 AstraZeneca): 

2 cases of acute MI <24 hours after mRNA vaccination:

Acute STEMI MI following AstraZeneca vaccination,?Kounis syndrome?:

Vaccine induced immune thrombocytopenia and thrombosis associated anterior ST-elevation myocardial infarction following AstraZeneca:



Hypertension following mRNA vaccination:


POTS (Postural Orthostatic Tachycardia Syndrome):

Postural orthostatic tachycardia syndrome after mRNA COVID-19 vaccine:

POTS following Pfizer:

Autonomic dysfunction post-inoculation with ChAdOx1 nCoV-19 vaccine



Isolated tachycardia in a 29yoF following Pfizer:

Tachycardia following Pfizer: 3 cases in those previously infected with COVID-19:


Long QT / Conduction Disturbance:

VT storm in long QT resulting from COVID-19 vaccine allergy treated with epinephrine:

Long QT syndrome following AstraZeneca:

Two cases of vaccine induced cardiac conduction disturbance following Pfizer and AstraZeneca:

Dizziness, HTN and new LBBB following AstraZeneca vaccination:

Frequent PVS and NSVT following 2nd dose of Pfizer:

Unmasked type 1 Brugada pattern without fever in a 32yoM following Pfizer:



Posttransplant lymphoproliferative disorder after AstraZeneca in a heart transplant recipient:


Risk of adverse events and reported relapse after COVID-19 vaccination in patients with IBD:



Gastroparesis following Pfizer:



14yoF with acute pancreatitis following Pfizer:

17yoM with acute pancreatitis following Pfizer:

71yoF with acute pancreatitis following Pfizer:

Pancreatitis injury after Pfizer, a case report:

Acute Necrotizing Pancreatitis following 2nd dose of Pfizer:

Acute Pancreatitis in a 96yoF following 1st dose of Pfizer:

Pancreas allograft rejection following AstraZeneca:



Cutaneous hypersensitivity reaction with acute hepatitis following Pfizer 2nd dose:

35yoF third month post partum with autoimmune hepatitis following vaccination:

Liver transplant in a 53yo healthy man due to vaccine induced autoimmune hepatitis and subsequent liver failure following Pfizer vaccination:

65yoM with autoimmune hepatitis following Moderna:

79yoM with AstraZeneca induced autoimmune hepatitis:

Three cases of autoimmune hepatitis following Pfizer:

A case of hepatotoxicity in 14yoF after receiving Pfizer vaccine:

Post-transplant autoimmune recurrence following Pfizer vaccination:

27yoF with autoimmune hepatitis following Pfizer:

82yoF with history of HCV treatment with autoimmune hepatitis following COVID-19 vaccination:

Development of hepatitis and colitis in a 52yoF with cancer during immunotherapy following Pfizer:

Severe de novo liver injury after Moderna vaccination-not always autoimmune hepatitis:

Liver injury and cytopenia in an adolescent following Pfizer:

Clinical significance of hepatosplenic thrombosis in VITT after AstraZeneca vaccination:

AMA-positive hepatitis in a 56yoF induced by Pfizer vaccine:

Hepatic artery occlusion following Astrazeneca:

Acute cholestatic hepatitis after Pfizer vaccine:

52yoF with autoimmune hepatitis following Moderna:

41yo F with Autoimmune hepatitis following Moderna:

76yoF with autoimmune hepatitis following Moderna Vaccination:

71yoF with Autoimmune hepatitis after mRNA vaccine (Moderna):

80yoF with autoimmune hepatitis following Pfizer:

63yoM with autoimmune hepatitis following Moderna:

61yoF with liver injury following Pfizer:

61yoF with autoimmune hepatitis following Pfizer:

35yoF with autoimmune hepatitis following Pfizer:

New Onset autoimmune hepatitis following mRNA vaccination in a 36yoF with Primary sclerosing cholangitis:

56yoF with autoimmune hepatitis following Moderna:

Two cases of autoimmune hepatitis following AstraZeneca:

Liver injury in a liver transplant patient following mRNA vaccination:

16 cases of liver injury following Pfizer and Moderna: a multicenter case series:

Reactivation of Hepatitis C infection following Pfizer in a 82yoF:–a-case–peer-reviewed-fulltext-article-IMCRJ?fbclid=IwAR3u0x1baFcAZz1eOrNsXsgmrlUYt0EJV2SmoXA75RiplFQbPrtSAIo2GAs



Inflammatory Bowel Disease triggered by Pfizer vaccination:

De Novo Pediatric Ulcerative Colitis trigger by Pfizer: a tale of 2 sisters:

Ischemic colitis in a 48yoF after 2nd dose of covid019 inactivated vaccine:

Sclerosing Cholangitis:

Unusual fever, HA, and abdominal pain in a healthy woman following AstraZeneca:

Hepatic vein thrombosis due to TTS following AstraZeneca:

3 cases of portal vein thrombosis following AstraZeneca:




ANCA glomerulonephritis after Moderna:

Case report: ANCA vasculitis with acute renal failure and pulmonary hemorrhage after Moderna:

New onset ANCA vasculitis after Pfizer:

ANCA associated Glomerulonephritis following Pfizer:

ANCA associated vasculitis presenting with Rhabdomyolysis and pauci-immune crescentic glomerulonephritis after Pfizer:

Anti-GBM nephritis with mesangial IgA deposits following Moderna:

Concurrent antiglomerular basement membrane (Anti-GBM) nephritis and ANCA glomerulonephritis in a 23yoM following 2nd dose Moderna:

Two adolescent cases of acute tubulointerstitial nephritis after 2nd dose Pfizer:

58yoF with Pfizer induced severe rhabdomyolysis with acute AKI requiring renal replacement therapy:

De novo and relapsing necrotizing vasculitis after mRNA vaccination, 5 cases: 4 cases of relapsing ANCA vasculitis and 1 de novo polyarteritis nodosa:

COVID-19 vaccination precipitating de novo ANCA associated vasculitis: clinical implications:

PTU-induced ANCA-associated vasculitis after Pfizer vaccination:

Relapsed ANCA associated vasculitis following AstraZeneca: A case series of two patients:

ANCA associated vasculitis following AstraZeneca:


Nephrotic Syndrome:

Nephrotic Syndrome following AstraZeneca:

New onset pediatric nephrotic syndrome following Pfizer:

Nephrotic syndrome and vasculitis following Pfizer, Moderna, and AstraZeneca:


Minimal Change Disease:

MCD relapse following Pfizer in a man in his mid-60s:

MCD relapse following Pfizer in a 34yoF:

Severe Minimal change disease relapse 3 days following Pfizer:

Minimal Change Disease with nephrotic syndrome and AKI following Pfizer in a 50yoM:

Minimal change disease in a 18yoM following Pfizer:

Minimal change disease in a 25yoF following 1st dose Moderna:

Minimal change disease following Pfizer in a living kidney donor:

2 cases of nephrotic syndrome with minimal change disease following Pfizer:

Minimal change disease in 80’s yoM following first dose of Pfizer:

Minimal change disease after 1st dose Pfizer 60yoM:

Minimal change disease and AKI in a 77yoM following Pfizer:

Minimal change disease 4 days after Pfizer in a 45yoF:

Minimal change disease in a 39yo after 1st dose of Pfizer:

Minimal Change disease in a 63yoF following Moderna:

Minimal change disease in a 43yoM following Moderna:

Relapse of minimal change disease with severe nephrotic syndrome in a 22yoM following Moderna:

Minimal Change disease and Severe AKI following AstraZeneca:

Relapse of Minimal Change disease in a 30yoM following AstraZeneca:

New onset Nephrotic syndrome due to Minimal Change disease following J&J:

2 cases of minimal change disease following vaccination:

3 cases of minimal change disease following 2nd dose of mRNA vaccine:

13 cases of new or relapsing minima change disease following mRNA vaccination:


Nephropathy / IGA Vasculitis:

Acute interstitial nephritis following AstraZeneca:

Sibling cases of IgA nephropathy (15yoM and 18yoM) following Pfizer:

IgA nephropathy in a 12yoM after 1st dose Pfizer:

IgA nephropathy relapse in a 54yoF following 2nd dose Moderna:

2 cases of macroscopic hematuria in children with IgA nephropathy remission following Pfizer (15yoF, 16yoF):

2 cases (19yoM, 50yoF), histologic correlates of gross hematuria following Moderna in patients with IgA nephropathy (recurrence of disease following vaccination):

Acute T-cell mediated rejection after Pfizer in a kidney transplant recipient:

Abrupt worsening of occult IgA nephropathy after first dose Pfizer in a Japanese woman in her 40s:

Development of IgA vasculitis with severe glomerulonephritis after Pfizer:

New onset kidney biopsy proven IgA vasculitis in a 47yoM following Moderna:

2 cases of IgA vasculitis following Pfizer (22yoM and 30yoM):

19 cases of IgA vasculitis post COVID-19 vaccination:

Acute interstitial nephritis in a 63yoM following Pfizer:

2 cases of acute interstitial nephritis with concurrent nephrotic syndrome  (69yoF and 60yoF) following AstraZeneca:

New-onset kidney diseases after COVID-19 vaccination: a case series (5 patients):

Glomerular disease in temporal association with COVID-19 vaccination: a series of 29 cases:

New onset biopsy proven nephropathies after COVID vaccination, 17 patients:

New-onset and relapse of nephrotic syndrome following COVID-19 vaccination, 27 patients in Japan, a questionnaire survey:

Clinical spectrum of gross haematuria following COVID-19 vaccination:

Atypical haemolytic uraemic syndrome following Pfizer in a 60yoF:

A case of acute interstitial nephritis following Pfizer:

Acute interstitial nephritis in a 45yoF following 2 doses of Pfizer:

Isolated renal arteritis with infarction after Pfizer COVID-19 vaccination:

13 cases of new or relapsed glomerulonephritis following mRNA vaccination:

48 cases of new onset and relapsed kidney histopathology following COVID-19 vaccination:

New onset lupus in a 68yoF following Pfizer:

New onset of Class III lupus nephritis with multi-organ involvement after Pfizer:

IgA nephropathy presenting as rapidly progressive glomerulonephritis in a 13yo following 1st dose of Pfizer:

IgA and crescentic glomerulonephritis following Pfizer:

17yoM with newly diagnosed IgA nephropathy with gross hematuria following Pfizer vaccination:

17yoF with IgA nephropathy following Pfizer:

IgA nephropathy in a 28yoF following Pfizer:

28yoF with flare up of IgA nephropathy following Pfizer:

29yoF with hematuria and likely IgA nephritis following Pfizer:

IgA nephropathy flare up following Moderna:

IgA Nephropathy after mRNA vaccine:

IgA nephropathy flare-up following vaccination:

IgA nephropathy following vaccination in a renal transplant recipient with a history of aristolochic acid nephropathy:

IgA nephropathy in 2 pediatric patients after Pfizer (13 and 17yo):

3 cases of IgA nephropathy patients developing exacerbations following mRNA vaccine:

2 cases of IgA nephropathy patients developing exacerbations following moderna:

2 cases of IgA Nephropathy patients developing hematuria after Pfizer:

Reactivation of IgA vasculitis following Moderna:

Reactivation of IgA vasculitis following Pfizer:

Case of IgA vasculitis following Pfizer vaccination:

IgA vasculitis following AstraZeneca:

IgA vasculitis with renal and skin involvement following vaccination:

Membranous nephropathy following mRNA vaccination:

Membranous nephropathy following Pfizer:



Gross hematuria after mRNA vaccination in two patients with histological and clinical diagnosis of IgA nephropathy:

Gross hematuria after Moderna vaccination for COVID in 2 patients with IgA nephropathy:

Distinct glomerular disease after mRNA vaccination: A Vigibase analysis:

Renal Thrombotic Microangiopathy following Pfizer in a 35yoM:

Glomerulopathies after vaccination against covid-19: four cases with three different vaccines in Argentina:




Cutaneous lupus erythematosus-like reaction following Pfizer:

Hyper-inflammation after COVID-19 mRNA vaccination: at the cross roads of multi-inflammatory disease and adult onset still’s disease

Immune mediated disease flares:

Local and systemic reactogenicity of Pfizer in patients with systemic lupus and rheumatoid arthritis:

Incidence of disease flare after Pfizer vaccination in patients with rheumatoid arthritis in remission:

11% of patients with rheumatic and MSK diseases report disease flare following 2 dose mRNA vaccination:


Macrophage Activation Syndrome:

Macrophage activation syndrome in a patient with adult-onset Still’s disease following first dose of Pfizer:


Still’s Disease:

Adult onset Still’s disease following AstraZeneca:

Adult onset Still’s disease after AstraZeneca:

Flare up of adult onset Still’s disease in a 37yoF following Pfizer:

Adult onset Still’s disease in a 43yoM following Pfizer:

Flare of adult onset still’s disease following Pfizer in a 49yoF:

Still’s disease in a 34yoF following AstraZeneca vaccination:

Adult onset Still’s disease in a 36yo following Pfizer:

Adult onset Still’s disease following mRNA vaccine:



New onset systemic lupus erythematosus beginning as class V lupus nephritis after COVID-19 vaccination:

Lupus nephritis flare following Moderna:

Lupus exacerbation:

New-onset systemic lupus erythematosus after AstraZeneca and alopecia areata after Pfizer:

Lupus exacerbation following mRNA vaccination:

27 cases of lupus flare following Pfizer:

New onset lupus following mRNA vaccination in a 27yoF:

Systemic lupus following AstraZeneca vaccination:

Relapse of class V lupus. Nephritis after mRNA vaccination:

Subacute cutaneous lupus erythematosus flare triggered by Moderna:

Subacute cutaneous lupus erythematous after Pfizer in a woman with primary biliary cholangitis:

New onset lupus, pancreatitis, and vasculitic rash in a 22yoF following Pfizer:

Emergence of new onset SLE following vaccination:


Hyperglycemic / Glucose:

COVID-19 vaccine and hyperosmolar hyperglycemic state:

Acute Hyperglycemic crisis: a case series of 3 patients following AstraZeneca:

Newly developed type 1 diabetes after Moderna in a 73yoF:

3 cases of exacerbation of hyperglycemia in patients with type 2 diabetes following AstraZeneca:

3 cases of hyperglycemic emergencies following Pfizer and Moderna:

Perturbation of blood glucose following vaccination, a review of 20 adults:

Hypertriglyceridemia following Pfizer vaccination in a patient with familial hypercholesteremia:



Silent thyroiditis following Pfizer, subacute thyroiditis following moderna, and Graves disease following Pfizer:

Subacute thyroiditis after COVID-19 vaccination:

SARS-CoV-2 vaccine-associated subacute thyroiditis: insights from a systematic review:

11 cases of COVID-19 vaccine induced subacute thyroiditis:


Subacute Thyroiditis:

Subacute thyroiditis following vaccination:

Subacute thyroiditis following Moderna vaccination:

Subacute thyroiditis following Pfizer: a tale of two sisters:

Subacute thyroiditis associated thyrotoxic periodic paralysis in a 26yoF following 2nd dose Moderna:

42yoF with subacute thyroiditis following Pfizer:

Thyroiditis after mRNA vaccine: a case series:

Two cases of subacute thyroiditis after Moderna and AstraZeneca:

4 cases of subacute thyroiditis after Pfizer vaccine:

Two cases of thyroiditis after Pfizer and AstraZeneca:

New onset Graves disease following Pfizer:

Graves disease following 2nd dose of Pfizer:

Graves disease following mRNA COVID-19 vaccination: case series:

New onset Graves disease and autoimmune diabetes mellitus following Pfizer:

Two cases of Graves disease following vaccination:

Two more cases of Graves disease following Pfizer:

Hyperthyroidism following vaccination:

Incidental findings on a TC99M-SESTAMIBI parathyroid scan post Moderna vaccination in a 48yoF:



5 cases of adrenal crisis following AstraZeneca:

Myositis in a 56yoF following mRNA vaccination:

COVID-19 vaccine induced cellulitis and myositis:

New onset giant cell arteritis following Pfizer:

2 cases of Löfgren’s syndrome following AstraZeneca and Moderna vaccination:

mRNA induced rhabdomyolysis and fasciitis:

Rhabdomyolysis after Moderna:

21yoM with Pfizer induced rhabdomyolysis:


Inflammation / Arthritis:

Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases:

Cubital tunnel syndrome temporally following Moderna in a 28yoF:

New-onset polymyalgia rheumatica in a 80yoF following Pfizer:

Polymyalgia rheumatica following covid-19 vaccination: a case series of ten patients:

Relapse of polymyalgia rheumatica in a 83yoM:

2 cases of polymyalgia rheumatica and 1 case of giant cell arteritis following COVID-19 vaccination:

50yoM with clinical syndrome of HSP including IgA leukocytoclastic vasculitis on skin biopsy following Pfizer:

Quadrilateral space region inflammation and other incidental findings on shoulder MRI following Pfizer COVID-19 vaccination:

Rash, arthritis, swelling, muscle weakness following AstraZeneca:

Self-limiting polymyalgia rheumatic-like syndrome following Moderna vaccination:

Polyarthralgia and Myalgia syndrome after AstraZeneca:

Severe polyarthralgia in elderly female following AstraZeneca:

Arthritis in the L elbow following vaccination:

Vasculitis and bursitis on 18F FDG-PET/CT following mRNA vaccination:

Remitting seronegative symmetrical synovitis with pitting edema following Pfizer:

COVID-19 vaccination and large0vessel giant cell arteritis:



40yoF with Henoch-Schonlein Purpura (HSP) following Pfizer:

45yoF with reactivation of HSP following Pfizer booster:

62yo with HSP following AstraZeneca:

76yoF with HSP following AstraZeneca:



New onset mainly guttate psoriasis after Pfizer:

2 cases of exacerbation of plaque psoriasis after Pfizer and CoronaVac:

Psoriatic spondyloarthritis exacerbation triggered by mRNA vaccine:

Psorasis exacerbation in a 46yoM after 2nd dose Pfizer:

14 cases of psoriasis activation following vaccination (Moderna, Pfizer, and AstraZeneca):

Pustuluar psoriasis following AstraZeneca:

Psorasis exacerbation after AstraZeneca:

Scleroderma renal crisis following mRNA vaccination:



Flares of mixed cryoglobulineamia vasculitis after vaccination

Pheochromocytoma crisis following J&J vaccination:



Treatment Guide to Thrombotic Thrombocytopenia Following Vaccination:

Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune/inflammatory syndrome expand?

Successful venous thromboprophylaxis in a patient with AstraZeneca induced VITT:

Coagulopathies after vaccination against SARS-COV-2 may be derived from a combo of spike protein and adenovirus vector-triggered signaling pathways:

Arterial thrombosis in an unusual site (ulnar artery) in a 68yoM following 3rd dose of Moderna:

Autoimmunity roots of the thrombotic events following COVID vaccination:

Thrombosis post COVID-19 vaccinations: Potential link to ACE pathways:

Changes in blood viscosity after COVID-19 vaccination:

Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with AstraZeneca:

The known knowns and known unknowns of vaccine-induced thrombotic thrombocytopenia:

Life-changing consequences of vaccine-induced immune-mediated thrombosis with thrombocytopenia:

Coagulopathies after vaccination against SARS-COV-2 may be derived from a combo of spike protein and adenovirus vector-triggered signaling pathways:

Vaccine induced thrombocytopenia and thrombosis: venous endotheliopathy leading to venous combined micro-macrothrombosis:

The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia:

Safety warning for AstraZeneca in patients with sickle cell disease:



Post-COVID vaccination acute hemolysis in an older man:

Autoimmune hemolytic anemia:

First and fatal case of autoimmune acquired factor XIII/13 deficiency after Pfizer in a 78yoF:

Autoimmune hemolytic anemia following Pfizer:

Autoimmune hemolytic anemia after Moderna with undetected pernicious anemia:

Cold agglutinin disease in a 45yoF following Pfizer:

Hemolytic crisis in a woman with cold agglutinin disease following mRNA vaccination:

Breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria on complement inhibitor following Moderna:

6 Paraoxysmal nocturnal hemoglobinuria patients with hemolytic crisis following Pfizer and Moderna:



Aplastic anemia in a 56yoM following Pfizer:

Aplastic anemia after COVID vaccination:



ITP and AIHA following Moderna:

95yoM with ITP following Pfizer:

2 cases of ITP following Pfizer:

ITP Exacerbation in previous stable patient following Pfizer:

ITP relapse post-Pfizer vaccine in a 28yoM:

ITP following Pfizer:

ITP following Pfizer:

ITP following booster dose of Pfizer:

ITP in a man in his mid 20s following Pfizer requiring splenectomy:

38yoF with ITP and myocarditis following Moderna:

Exacerbation of ITP following initial and booster dose of Pfizer, 93 patients:

Secondary ITP and resulting hemorrhage and hematoma after minor oral surgery after Pfizer:

ITP and diffuse papular rash following Moderna:

ITP following Astrazeneca:

ITP in 1st trimester of pregnancy 13 days following vaccination in the US:

20yoF with ITP following Pfizer:

22yoM with ITP following Pfizer:

24yoF with ITP following Pfizer:

25yoF with ITP exacerbation following Pfizer:

26yoF with ITP and acute liver injury following Moderna:

26yoF with ITP following Moderna:

28yoM with ITP following AstraZeneca:

37yoF with ITP following Pfizer:

39yoF with ITP following Pfizer:

41yoF with secondary ITP following Pfizer:

41yoM with ITP following AstraZeneca:

54yoF with ITP following Pfizer:

63yoF with ITP following Johnson and Johnson:

67yoF with ITP following Pfizer:

68yoF with ITP in Korea following AstraZeneca:

68yoF with ITP following Moderna:

69yoF with refractory ITP following Pfizer:

74yoM with ITP following Moderna:

84yoM with ITP following Pfizer:

86yoM with ITP following AstraZeneca:

2 cases of ITP following AstraZeneca:

3 cases of ITP following Pfizer and Astra Zeneca:

3 cases reports of ITP following Pfizer and J&J:

57yoF with myocarditis and hypopotassemia after Pfizer:

74yoM with ITP following Pfizer:

Acquired hemophilia A in a 39yoF following 1st dose Pfizer:

69yoM with acquired hemophilia A after 2nd dose COVID vaccination:

Acquired hemophilia A in a 72yoM and concurrent diagnosis of pleomorphic dermal sarcoma following Moderna booster:

Acquired hemophilia A in a 72yoM following Pfizer:

Acquired hemophilia A and bullous pemphigoid in a 77yoM following Moderna:

Acquired hemophilia A in a man in his 80s after Pfizer:

Acquired hemophilia A following Pfizer, successfully treated with prednisolone and rituximab:

4 cases of acquired hemophilia A after Pfizer:

3 cases: recurrent AvWD and acquired hemophilia A after Moderna, PNH flare following Moderna, and ITP flare following Moderna:

3 cases of acquired hemophilia A after mRNA vaccine, investigation into possible mechanism:

3 cases of ITP, 2 in chronic individuals and 1 in a healthy individual, following Pfizer and Moderna:

10 cases of ITP following COVID-19 vaccination:

3 cases of ITP in elderly patients following vaccination:

4 cases of severe ITP following Pfizer, Moderna, and AstraZeneca:

20 cases of ITP following Pfizer and Moderna vaccination:

21 cases of ITP following Pfizer and AstraZeneca:

36 Cases of ITP following Pfizer and Moderna:

77 denovo cases of ITP and 19 ITP exacerbation following vaccination:

12% of chronic ITP patients have exacerbation of ITP in 2-5 days following vaccination:


Thrombolytic / Thrombocytopenia

CoV-2 vaccination in patients with autoimmune cytopenias: the experience of a reference center:

PE, TIA, and thrombocytopenia after J&J:

Superior ophthalmic Vein Thrombosis and Thrombocytopenia following AstraZeneca:

DVT and PE and positive HIT panel following mRNA Vaccine:

An unusual presentation of acute DVT after moderna vaccine:

3 patients with venous thromboembolism following mRNA vaccination:

Thrombosis with Thrombocytopenia following Moderna:

34yoF with vaccine induced thrombotic thrombocytopenia following Moderna:

Thrombotic thrombocytopenia following Pfizer vaccination in a Japanese Patient:

Case report: vaccine-induced immune thrombotic thrombocytopenia in a pancreatic cancer patient after mRNA vaccination:

Case study of Thrombosis and Thrombocytopenia following AstraZeneca:

Eltromopag for refractory vaccine-induced immune thrombotic thrombocytopenia in a 64yoF following AstraZeneca vaccination:

TTP Following Pfizer:

Acquired TTP following Pfizer:

TTP in a 25yoM following Moderna:

Clinical relapse of immune mediated TTP in a 28yoF following Pfizer:

Denovo iTTP episode in a 38yoF following Pfizer:

Acquired TTP in a 61yoM following Pfizer:

Case series of patients who developed acquired TTP within several days of Pfizer:

TTP in an adolescent following Pfizer:

Flare of compensated congenital TTP following vaccination:

Thrombocytopenia in a teen with sickle cell disease following Pfizer:

5 cases of prothrombotic immune thrombocytopenia after AstraZeneca:

20 cases of Thrombocytopenia following Pfizer and Moderna:

Review of 50 cases of thrombocytopenia following Astrazeneca, Pfizer, Moderna:

68yoF with extensive thrombosis after AstraZeneca:

Thrombotic Thrombocytopenia after AstraZeneca: Autopsy findings:

3 cases of adolescents with Pfizer induced TTP:

Fatal ICH due to Thrombotic Thrombocytopenia following AstraZeneca:

Five cases with a combination of cerebral venous thrombosis, intracerebral hemorrhage and thrombocytopenia following AstraZeneca:



Late Onset VITT with cerebral venous sinus thrombosis:

Confusion and abdominal pain due to VITT following vaccination:

Fatal thromboembolism in a patient with preexisting thrombocytopenia following AstraZeneca:

Malignant CVA due to VITT following AstraZeneca:

Anti-platelet factor 4 IgG levels in VITT: persistent positivity through 7 months:

Thrombosis patterns and clinical outcome of VITT: a systematic review and meta-analysis:

Second dose VITT: rare but real:

Mechanisms of immunothrombosis in VITT compared to natural COVID infection:

3 cases of immune thrombocytopenia following AstraZeneca in Thailand:



New onset evans syndrome associated with systemic lupus erythematosus after Pfizer vaccination:

Skin, nose, and gingival bleeding episodes after AstraZeneca: a large population-based cohort study:

Haemophagocytosis and atypical lymphocytes on bone marrow biopsy following vaccination:

Hemophagocytic lymphohistiocytosis (HLH) in a 14yoF requiring VA ECMO:

3 cases of HLH following AstraZeneca:

Idiopathic ipsilateral external jugular vein thrombophlebitis after Pfizer vaccination:

Possible risk of thrombotic events following AstraZeneca in women receiving estrogen:

Blood clots and bleeding events following Pfizer and AstraZeneca: an analysis of European data:

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with AstraZeneca in Denmark and Norway: a population based cohort study:

Association of AstraZeneca and Pfizer with major venous, arterial, or thrombocytopenic events: a population based cohort study of 46 million adults in England:

Isolated thrombosis after COVID-19 vaccination: case series:

Arterial thrombosis following 1st dose AstraZeneca: a case series:




Temporal metabolic response to mRNA vaccinations in oncology patients:

Coordination and optimization of FDG PET/CT and vaccination; lessons learned in the early stages of mass vaccination:

Post vaccination lymphadenopathy: report of cytological findings from fine needle aspiration biopsy:

Axillary lymphadenopathy after vaccination in a woman with breast cancer:

Fine needle aspiration in a vaccine associated lymphadenopathy:

Hypermetabolic lymphadenopathy following Pfier, incidence assessed by FDG PET-CT and revelance to study interpretation, a review of 728 vaccinated patients:


Lymphadenopathy / Adenopathy:

Lymphadenopathy following vaccination: imaging findings review:

Axillary lymphadenopathy following mRNA vaccination

Ipsilateral axillary adenopathy following mRNA vaccination:

Deep axillary lymphadenopathy after vaccination: a case report:

Unilateral axillary lymphadenopathy following vaccination: a case report and imaging findings:

Unilateral axillary lymphadenopathy after vaccination:

Axillary adenopathy following vaccination, a new diagnostic dilemma:

Unilateral axillary adenopathy in the setting of covid-19 vaccine:

COVID-19 vaccination (Pfizer) simulating lymph node progression in a patient with prostate cancer:

Multifocal lymphadenopathies with polyclonal reactions primed after EBV infection in a Moderna vaccine recipient:

COVID-19 vaccine induced subclinical axillary lymphadenopathy on screening mammogram:

Unilateral axillary adenopathy following vaccination: a multimodality pictorial illustration and review of current guidelines:

False positive axillary lymph nodes on FDG PET/CT resulting from covid-19 immunization:

4 cases of axillary adenopathy following mRNA vaccination:

COVID-19 vaccination associated axillary adenopathy: imaging findings and follow-up recommendations in 23 women:

163 cases of axillary adenopathy following Pfizer:

mRNA vaccination: age and immune status and its association with axillar lymph node PET/CT uptake, a review of 426 patients:

Ipsilateral avid axillary lymph node update at FDG PET/CT persists in 29% of patients 7-10 weeks after 2nd dose of Pfizer:

Incidence of axillary adenopathy on Breast Imaging following Vaccination:

Breast radiation recall phenomena after AstraZeneca: A case series:

Regional lymphadenopathy following vaccination: literature review and considerations for patient management in breast cancer care:

Axillary lymphadenopathy at the time of vaccination: ten recommendations from the European society of breast imaging:

Evolving bilateral hypermetabolic axillary lymphadenopathy on FDG PET/CT following 2-dose COVID-19 vaccination:

Axillary lymph nodes hypermetabolism after Pfizer in cancer patients underoing 18F-FDG PET/CT: a cohort study:

Reactive axillary lymphadenopathy to covid-19 vaccination on F-FDG PET/CT:

Association of COVID-19 mRNA vaccine with ipsilateral axillary node reactivity on imaging:

Supraclavicular lymphadenopathy following Pfizer:

Rare case of contralateral supraclavicular lymphadenopathy after vaccination: CT and ultrasound findings:

Supraclavicular lymphadenopathy after vaccination in Korea: a serial follow-up using ultrasonography:

Supraclavicular lymphadenopathy following vaccination: an increasing presentation to the two-week wait neck lump clinic?

Vaccination and low cervical lymphadenopathy in the two week neck lump clinic- a follow up audit:

Cervical lymphadenopathy following Pfizer

13 cases of Cervical lymphadenopathy:

50yoM with adenopathy following Pfizer:

Review of 24 cases of lymphadenopathy and their ultrasound findings in the US:

Kikucki-Fujimoto disease following Pfizer:

2 cases of Kikuchi-Fujimoto Disease following Pfizer:

Mammographic and sonographic findings in the breast and axillary tail following vaccination:

Management of unilateral axillary lymphadenopathy detected on breast MRI in the era of covid-19 vaccination:

Mitigating the impact of COVID-19 vaccinations on patients undergoing breast imaging examinations: a pragmatic approach:

COVID-19 vaccine related axillary and cervical lymphadenopathy in patients with current or prior breast cancer and other malignancies: cross sectional imaging findings on MRI, CT, and PET-CT:

The challenge of staging breast cancer with PET/CT in the era of covid vaccination:

Vaccination and breast cancer surgery timing:

Vaccine related unilateral axillary lymphadenopathy: pattern on screening breast MRI:

Evolution of lymphadenopathy at PET/MRI after vaccination:

Axillary lymphadenopathy after COVID vaccination in patients with thoracic malignancy:

DOTATATE PET-avid axillary lymph node after injection of the Johnson & Johnson:

DOTATATE-avid bilateral axillar and subpectoral lymphadenopathy induced from mRNA vaccination visualized on PET/CT:

DOTATOC-avid lymphadenopathies induced by mRNA vaccination:

3 cases of supraclavicular and axillary lymphadenopathy induced by vaccination on 18F-Fluorthanatrace, 68Ga-DOTATATE, and 18F-Fluciclovine PET/CT:

FDG uptake in axillary lymph nodes after vaccination: a pitfall case of highly suspicious lymph nodes metastases of malignant melanoma:

Moderna vaccination mimicking lymph-node progression in a patient with melanoma:

COVID-19 vaccine as cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma:

Pfizer vaccination manifesting as incidental lymph node uptake on 18F-FDG PET/CT in a melanoma patient:

Axillary adenopathy following AstraZeneca resulting in possible misinterpretation of PET scan in metastatic melanoma patient:

8 patients where mRNA vaccine mimics lymph node metastates in patients undergoing skin cancer follow-up:

Hypermetabolic reactive lymphadenopathy following 3rd COVID-19 vaccination in a breast cancer patient and a patient with squamous cell carcinoma of the head and neck:

False Positive FDG PET CT after vaccination in a woman treated for metastatic breast cancer:

COVID-19 vaccine related axillary lymphadenopathy in breast cancer patients: case series with a review of the literature:

Pfizer vaccine related local FDG uptake in a lymphoma patient:

mRNA vaccination induced lymphadenopathy mimics lymphoma progression on FDG PET/CT:

Avid left axillary nodes and intense diffuse splenic uptake and moderate diffuse bone marrow uptake on PET 1 week after vaccination:

Limiting screening mammography recalls for vaccine-induced adenopathy, a single institution experience:


FDG-PET / PET-CT findings:

Vaccination effect on tracer uptake with FDG-PET/CT:

18-FDG-Avid lymph nodes after covid-19 vaccination on PET/CT:

18-FDG-Avid lymph nodes after covid-19 vaccination:

FDG update in axillary lymph nodes and deltoid muscle after mRNA vaccination: a cohort study to determine incidence and contributing factors using a multivariate analysis:

COVID-19 vaccination induced axillary nodal update on 18F FDG PET/CT:

Prevelance and significance of hypermetabolic lymph nodes detected by 18F FDG PET/CT after vaccination: a systematic review and meta-analysis:

AstraZeneca vaccination included lymphadenopathy on 18F choline PET/CT-not only an FDG finding:

Abnormal PET following vaccination:

Positive PET following vaccination:

Vaccine related lymph node activation-patterns of uptake on PET CT:

Lymphadenopathy in vaccine recipients: a diagnostic dilemma in oncologic patients:

The day after mass COVID vaccination: higher hypermetabolic lymphadenopathy detection on PET/CT and impact on oncologic management:

Frequency and characteristics of nodal and deltoid FDG and C-Choline update on PET performed after mRNA vaccination:

COVID-19 vaccination-related update on FDG PET/CT: an emerging dilemma and suggestions for management:

Subcutaneous uptake on 18F PET/CT: a case report of possible amyloid-beta immune-reactivity after vaccination:

Rapid progression of Angioimmunoblastic t cell lymphoma following Pfizer Booster:



Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report



Thymic hyperplasia after mRNA vaccination:

Fatal systemic capillary leak syndrome after Johnson and Johnson vaccination in a multiple myeloma patient:

Rituximab-induced acute lympholysis and pancytopenia after Moderna in a 71yoM with b-cell lymphoplasmacytic lymphoma:

Systemic capillary leak syndrome in a middle age woman following Pfizer:

Adverse reactions following vaccination in patients with cancer undergoing treatment:

Rapid development of radiation recall pneumonitis in a non-small cell lung cancer patient immediately following second dose of Moderna:

Radiation recall pneumonitis on FDG/ PET/CT triggered by mRNA vaccination:

Radiation recall pneumonitis in a non-small cell lung cancer patient following Pfizer:



2 cases of denovo dermatomyositis and inflammatory myositis following Pfizer:

Acute, ulcerative, sarcoidal tattoo reaction in a 38yoF following 2nd dose Moderna:

Eosinophilic cellulitis following Pfizer in a 12yoM:

Pemphigus vulgaris in a 60yoF following 2nd dose Pfizer:

A severe case of trichophyton rubrum-caused dermatomycosis exacerbated after Pfizer in a 75yoM:

Haemorrhagic bullous pyoderma gangrenosum in a 46yoF following AstraZeneca:

Pemphigus vulgaris in a 44yoM following 2nd dose AstraZeneca:

Morbilliform rash in a 30yoM following Pfizer:

6 cases of pityriasis rosea following Pfizer:

Pityriasis rosea associated with covid-19 vaccination: a common rash following administration of a novel vaccine:

23yoF with pityriasis rosea-like rash after Pfizer: a case report and review of the literature:

40yoM with pityriasis rosea-like eruptions following Modera: a case report and literature review:

52yoF with pityriasis rosea-like eruption after AstraZeneca:

53yoF with pityriasis rosea-like cutaneous eruption after AstraZenca:

56yoF with inverse pityriasis rosea after J&J:

Dermatomyositis-like rash and inflammatory myopathy after Moderna:

Dermatomyositis following Pfizer vaccination in a 43yoF:

Unilateral linear purpuric rash heralding AstraZeneca induced ITP:

60yo with Steven Johnson Syndrome:

Steven Johnson Syndrome following Pfizer:


Pemphigus Vulgaris

Pemphigus vulgaris after COVID-19 vaccination: one new onset and two cases with severe aggravation:

An unusual presentation of pemphigus foliaceus following vaccination:

A case of erythroderma with elevated serum immunoglobulin E and thymus and activation-regulated chemokine levels following mRNA vaccination:

Spontaneous urticaria after Pfizer vaccine:

Pityriasis-rosea like eruption post-vaccination in a young male:

Pityriasis rosea, pityriasis rosea-like eruptions and herpes zoster after covid-19 and covid-19 vaccination:

Pityriasis rosea following Pfizer:

Pityriasis lichenoides et varioliformis acuta after SARS-CoV2 infection a relapse after vaccination:

19yoM with Pityriasis rosea following AstraZeneca:

29yoM with Pityriasis rosea after Moderna:

35yoM with Pityriasis rosea-like eruption after Pfizer:

40yoM with Pityriasis rosea after Moderna:

66yoM with Pityriasis rosea after Pfizer:

1 case of Pityriasis rosea and 3 cases of urticaria following Pfizer:

2 cases of Pityriasis rosea-like eruptions following Pfizer:

Pityriasis rosea following Moderna vaccination, a case series:

Vaccine induced Pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature:

Ezematiform eruption after Pfizer:

Two cases of papulo-pustular rosacea-like eruptions following Pfizer and AstraZeneca:

Pityriasis rubra pilaris following Astra Zeneca:

Pityriasis rubra pilaris in 72yoM following Astra Zeneca:

Pityriasis Rubra Pilaris like eruption following Pfizer:

Lymphomatoid drug reaction developed after Pfizer vaccine manifesting as pityriasis lichenoides et varioliformis acuta-like eruption:

Lichenoid drug eruption following Pfizer:

Lichenoid drug eruption after COVID-19 vaccination:

3 cases of new onset acral hand lesions following mRNA vaccine:

2 patients with eczematous cutaneous reactions following Pfizer:

Case study of 19 patients with cutaneous adverse reactions following vaccination:

New onset synovitis and palmoplantar psoriasis flare up after Pfizer:

Exacerbation of Hailey-Hailey Disease following mRNA vaccination:

New onset lichen planus following Pfizer:

COVID-vaccine induced lichen planus on areas previously affected by vitiligo:

Lichen striatus:

46yoM with lichen planus eruption following AstraZeneca: a case report and review of literature:

Linear IgA bullous dermatosis following AstraZeneca in a 61yoM:

60yoF with vitiligo after AstraZeneca:

Persistent pruritic morbilliform rash after 2nd dose Pfizer in a 59yoM:

Lichen planus flare following COVID-19 vaccination:

Purpura annularis telangiectodes following Pfizer:

Flagellate Purpura following AstraZeneca:

Pigmented purpuric dermatosis after Pfizer vaccine:

Symmetrical drug related intertriginous and flexural exanthema like eruption following AztraZeneca:

Vitiligo following Pfizer:

Vitiligo in a Ulcerative Colitis Patient following mRNA vaccination:

Bacillus Calmette-Guerin scar flare after mRNA vaccination:

Palms and Soles Itchiness following Pfizer:

Resistant pruritis skin rash following Pfizer:

Morphea (70yoF) after AstraZeneca and a second patient after COVID-19 infection:

Necrotic eschars at injection sites one week after 2nd dose of Pfizer:

Acral hemorrhage after second dose of vaccination:

Facial Pustular Neutrophilic Eruption following mRNA vaccine:

Acute generalized exanthematous pustulosis induced by Moderna:

AstraZeneca induced acute localized exanthematous pustulosis:

Delayed local skin reactions:

Delayed skin reactions following mRNA vaccine:

11 patients with delayed skin reaction after mRNA vaccination:

Additional 12 Patients with Delayed Local Reactions:

16 patients delayed hypersensitivity reactions after Moderna:

138 Delayed Hypersensitivity Reactions following vaccination:

Delayed local Hypersensitivity reactions: a 6 month retrospective study:

Delayed cutaneous adverse reaction to AstraZeneca in a breastfed female infant: coincidence or rare effect?:

Delayed cutaneous hypersensitivity reaction following AstraZeneca:

Cutaneous skin manifestation following Moderna with Hypersensitivity reaction Histopathology:

Assessment of delayed large local reactions after 1st dose of mRNA vaccine in Japan:

2 cases of delayed local reactions following Moderna:

4 cases of cutaneous hypersensitivity reactions following Moderna:

5 Japanese cases of delayed large local reactions to Pfizer vaccination:

13 cases delayed local reactions following mRNA vaccine:

COVID Vaccine arm:

COVID arm following Moderna: histologic features:

COVID arm following Moderna detected by MR neurography:

Covid vaccine arm may present after both mRNA vaccines vaccination:

405 cases of dermatologic reactions following Pfizer, Moderna, and Astra Zeneca:

Erythema Migrans like rash after Moderna:

Bullous neutrophilic dermatosis with severe acral oedema post mRNA vaccination:

Bullous pemphigoid after 2nd dose Pfixer in a 78yoM:

Bullous pemphigoid associated with covid-19 vaccines: an Italian multicentre study:

Bullous Drug Eruption Rash following Moderna:

Bullous eruption following Pfizer:

Bullous Fixed Drug Eruption following AstraZeneca:

Bullous pemphigoid triggered by covid-19 vaccine (Pfizer): rapid resolution with corticosteroid therapy:

Atypical erythema multiforme related to Pfizer vaccine:

Erythema multiforme after AstraZeneca:

Erythema multiforme reactions after Moderna and Pfizer: a case series:

Generalized erythema multiforme like rash following Pfizer in a 78yoM:

A flare up of pre-existing erythema multiforme following Pfizer:

Prompt onset of Rowell’s syndrome following 1st dose Pfizer:

Annular plaques mimicking Rowell’s syndrome following mRNA vaccines: an overlooked phenomenon?

4 cases of oral erythema multiforme after Pfizer (15, 55, 49, and 20yo):

Cutaneous adverse events related to COVID-19 vaccines: a cross-sectional questionnaire-based study of 867 patients:

Cutaneous reactions to covid-19 vaccine at dermatology primary care (21 patients):

Soft Tissue Filler Inflammatory Reaction after vaccination

Clinical and pathologic correlation of cutaneous covid-19 vaccine reactions including V-REPP: a registry-based study:

Cutaneous complications of mRNA and AstraZeneca vaccines: a worldwide review:

COVID related cutaneous manifestations: a systematic review:

A systematic review on mucocutaneous presentation after vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders:

New onset leukocytoclastic vasculitis following COVID-19 vaccination:

Erythema multiforme following Pfizer:

Cutaneous adverse reactions associated with COV-2 vaccines:

Cutaneous adverse events related to COVID-19 vaccines: a cross-sectional questionnaire-based study of 867 patients:

Soft Tissue Filler Inflammatory Reaction after vaccination:

;Immune Response to fillers and breast implants after vaccination:

Breast Implant seroma after mRNA vaccine:

L Breast Implant Capsular Contracture following Moderna vaccination:

COVID-toes after mRNA vaccination:

Systemic vasculitis in an 80yoM following mRNA vaccination demonstrated on FDG/PET:

2 cases of Vitiligo triggered by COVID-19 vaccination:

Bacillus Calmette-Guerin scar erythema in a 14yoF post Pfizer vaccination:

Leukocytoclastic vasculitis:

Schnitzler syndrome after covid-19 vaccination:

Urticarial vasculitis after covid-19 vaccination: a case report and literature review:

Eosinophilic granulomatosis with polyangiitis in an elderly female following 2nd dose Moderna:

Generalized papulovesicular eruption as a side effect of Pfizer vaccine:

New onset leukocytoclastic vasculitis following COVID-19 vaccination:

Leukocytoclastic vasculitis after Pfizer:

Leukocytoclastic vasculitis flare following Pfizer:

Leukocytoclastic vasculitis in a 42yoF after Pfizer:

Leukocytoclastic vasculitis after Pfizer vaccine booster:

Leukocytoclastic vasculitis in a 68yoF following AstraZeneca:

Cutaneous leukocytoclastic vasculitis induction following AstraZeneca:

Cutaneous vasculitis following AstraZeneca:

Cutaneous vasculitis following AstraZeneca:

Leukocytoclastic vasculitis as a cutaneous manifestation of the AstraZeneca vaccine:

Leukocytoclastic vasculitis after exposure to AstraZeneca vaccine:

Urticarial Vasculitis following vaccination:

Urticarial Vasculitis:

Small vessel vasculitis after Astra Zeneca:

Sweet-like syndrome and multiple covid-arm syndrome following covid-19 vaccine: specific patterns in a series of 192 patients:

Acute Posterior multifocal placoid pigment epitheliopathy after Pfizer in a 17yoM:

Possible case of mRNA vaccine induced small vessel vasculitis:

Cutaneous small vessel vasculitis following J&J:

Cutaneous lymphocytic vasculitis following mRNA vaccine:

Pfizer induced reactivation of varicella and resulting small vessel vasculitis:

Granulomatous vasculitis after AstraZeneca:

Immune complex vasculitis following Pfizer:

Relapse of microscopic polyangiitis after Pfizer vaccination: a case report:

De novo vasculitis after Moderna:

2 cases of skin color discoloration following mRNA vaccination:

A case series of rare cutaneous adverse events following vaccination:

Moderna Vaccine Induced Skin Rash:

A Case series of Cutaneous vaccine reactions at Loma Linda University:

Reactivation of BCH vaccination scars after vaccination with mRNA vaccines:

Clinicopathological features of cutaneous reactions after mRNA vaccines, 11 cases:

3 cases of vesiculobullous non-IgE-mediated cutaneous reactions to Pfizer:

Sweet Syndrome following Pfizer:

A case of generalized sweet’s syndrome with vasculitis triggered by J&J vaccination: 

Bullous sweet syndrome following AstraZeneca:

A narrative review of cutaneous and hypersensitivity reactions:

Clinical and histopathological spectrum of delayed adverse cutaneous reactions following covid-19 vaccination, a review of 12 cases:

SARS-CoV-2 Vaccines and the Skin:

COVID-19 vaccines and cutaneous adverse reactions; a review:

COVID-19 vaccines and the skin: the landscape of cutaneous vaccine reactions worldwide:

Cutaneous reactions reported after Moderna and Pfizer vaccination: a registry based study of 414 cases:

Response to McManon et al’s…414 cases:

Cutaneous findings following COVID019 vaccination: review of world literature and own experience:

Cutaneous and allergic reactions due to covid-19 vaccinations review:

Skin reactions to covid-19 vaccines: an AAD/ILDS registry update on reaction location and COVID vaccine type: 

Alopecia areata following COVID-19 vaccination:

Alopecia areata in a 31yoM following 2nd dose of Pfizer:

Alopecia areata in a 61yoF after 2nd dose Pfizer:

3 cases of recurrence of alopecia areta after Pfizer and AstraZeneca in Italy:

9 cases of alopecia areata after covid vaccination:

The role of COVID infection and its vaccine in various types of hair loss:




COVID-19, COVID-19 vaccinations, and subsequent abnormalities in the retina: causation or coincidence?

After the storm: ophthalmic manifestations of COVID-19 vaccination:

Ocular adverse events after covid-19 vaccinations:

Bilateral acute posterior multifocal placoid pigment epitheliopathy (APMPPE) following mRNA vaccine:

Ocular manifestations after receiving COVID-19 vaccine: a systematic review:

Ocular adverse reactions: a review and update:

Ocular inflammatory events following COVID-19 vaccination: a multinational case series:


Macular Neuroretinopathy:

Acute Macular Neuroretinopathy after AstraZeneca

Acute macular neuroretinopathy following Pfizer:

Central serous chorioretinopathy following Pfizer (38yoM military physician):

4 cases of serous chorioretinopathy following Pfizer (35-65yo):

Bilateral multifocal central serous retinopathy following Pfizer in a 32yoF:

Acute Central Serous Retinopathy after Pfizer:

Bilateral panuveitis mimicking vogt-koyanagi-harada disease following AstraZeneca:


42 cases of Uveitis and other ocular complications following COVID-19 vaccination:

Reduction of Visual Acuity following Pfizer:


Corneal Graft Rejection:

Corneal graft rejection after Pfizer vaccination:

Corneal graft rejection following Pfizer:

Acute corneal graft endothelial graft rejection following Pfizer:

Full thickness corneal transplant rejection 3 days following Moderna:

2 cases of corneal graft rejection following Pfizer: 

2 cases of corneal graft rejection following Pfizer:

4 cases of Corneal graft rejection following Moderna:

Corneal graft rejection following AstraZeneca:

Retinal vein occlusion following COVID-19 vaccination:

Combined central retinal artery and vein occlusion with ischemic optic neuropathy after Pfizer:

Central retinal artery occlusion after mRNA vaccination:

Bilateral Retinal Detachments 10 days after mRNA vaccination 22yoF :

Retinal venous occlusion in a 28yoM after 3rd dose of AstraZeneca:

Exacerbation of branch retinal vein occlusion post Pfizer:

CMV reactivation and pericarditis following AstraZeneca:


Vein Occlusion / Retinal Necrosis

6 cases of retinal vascular events following Pfizer, Moderna, AstraZeneca vaccination:

Central Retinal Vein Occlusion occurring immediately after 2nd dose of mRNA vaccine:

Central vein occlusion after mRNA vaccination: a case report:

Combined central retinal artery and vein occlusion shortly after mRNA vaccination:

Acute retinal necrosis associated with reactivation of varicella zoster virus after Pfizer vaccination in 78yoM:

Acute retinal necrosis associated with reactivation of varicella zoster virus after Pfizer vaccination in 62yoM:

Acute retinal necrosis associated with reactivation of varicella zoster virus after Pfizer vaccination in 71yoM:


Oculomotor Palsy

Transient Oculomotor palsy following mRNA. Vaccine:


Anterior Uveitis

Anterior Uveitis following Pfizer:

21 cases of Uveitis following mRNA vaccination:


Optic Neuropathy

A case of bilateral arteritic anterior ischemic optic neuropathy and a case of bilateral acute zonal occult outer retinopathy after mRNA vaccination:


Herpes Keratitis

Reactivation of herpes simplex keratitis following AstraZeneca vaccination:

Relapse of stromal herpes keratitis following mRNA vaccination:

2 cases of Ipsilateral zoster opthalmicus after Moderna and Johnson and Johnson:

2 cases of herpes zoster ophthalmicus following vaccination:

Bilateral immune mediated keratolysis following AstraZeneca:



Vaccination and Bilateral Multifocal Choroiditis:

34yoM with bilateral multifocal choroiditis following 2nd dose vaccination:

Acute painless bilateral blurring of vision following Pfizer due to Vogt-Koyanagi-Hara disease:

Multimodal Imaging of acute foveolitis following COVID-19 vaccination:

Eyelid erythema after Pfizer vaccination:

Transient eyelid edema following Pfizer:

Disc edema in one eye and central serous chorioretinopathy in the other following AstraZeneca:


Ear, Nose and Throat:

Persisting, unilateral tinnitus after mRNA vaccine:,_unilateral_tinnitus_22_days_after.175.aspx

3 cases of Tinnitus following mRNA vaccination:

COVID-vaccine associated tinnitus: a review of VAERS:

18 cases of idiopathic sensorineural hearing loss, tinnitus, and/or vertigo following Moderna/Pfizer:

18 cases of idiopathic sensorineural hearing loss, tinnitus, and/or vertigo following Moderna/Pfizer:

Tinnitus/cochleopathy following AstraZeneca:

3 cases of sudden sensorineural hearing loss following Pfizer and AstraZeneca:

Vestibular neuritis in a 54yoM following Pfizer:

Bilateral Vocal Fold Paralysis after 3rd dose Pfizer requiring intubation and tracheostomy:

Ulcers of bilateral palate mucosa following Moderna in a 58yoF:

Lipschutz ulcers after AstraZeneca:



Herpes Zoster following Moderna:

10 cases of herpes zoster following covid vaccination:

2 cases (80yoF, 69yoF) of herpes ophthalmicus following Pfizer:

Herpes Zoster reactivation following Moderna:

Herpes Zoster following mRNA vaccination in a patient with ankylosing spondylitis:

5 cases of Herpes Zoster following Pfizer:

Zoster meningitis after Pfizer vaccination in a 39yoF:

1 case HSV meningitis and 2 cases herpes zoster ophthalmic following Pfizer:

Ramsy Hunt syndrome following mRNA vaccination:

L-lysine in herpesvirus reactivation after AstraZeneca vaccine: a minor literature review and case report:

A case series of Herpes Zoster following AstraZeneca:

2 cases of herpes zoster following Pfizer:

2 cases of herpes zoster in healthy young adults following vaccination:

3 cases of Herpes Zoster following Vaccination (Moderna and AstraZeneca):

3 cases of Herpes Zoster after covid vaccination in patients with chronic urticaria being treated with cyclosporine:

4 cases of Herpes Zoster (2 pfizer, 2 astrazeneca):

6 cases of Herpes Zoster following Pfizer:

COVID-19 vaccines and herpes infection:

A case of varicella-zoster virus after Pfizer:

Varicella zoster reactivation and mRNA vaccines as a trigger:

40 cases of HSV and VZV reactivation following mRNA vaccination:



New-onset autoimmune phenomena post COVID-19 vaccination: 

American College of Rheumatology Guidance for COVID-19 vaccination: theoretical risk exists for AIIRD flare and potential risk for new onset autoimmunity:

Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome?

Analysis of neurologic adverse events reported in VigiBase from COVID-19 vaccines:

A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination

Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to “potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases”


MIS-V, Multisystem Inflammatory Syndrome:

MIS, Pericarditis, and HLH in a 36yoF following Astrazeneca:

Multisystem inflammatory syndrome in an adult following Pfizer (MIS-V):

MIS in 2 adults with short interval between COVID-19 infection and subsequent vaccination:

Two cases of MIS-V: 12yoM and 14yoM:

Two cases of MIS-V: 15yoF and 17yoF:

MIS-V in a 16yoM 3weeks after booster vaccination:

MIS-V in a 21yoM following 2nd dose of Pfizer:

MIS resulting in reversible autoimmune cardiomyopathy in a 25yoM following 3rd dose of COVID vaccination:

MIS-V with erythema multiforme-like rash in a 62yoM following Pfizer:

Multisystem inflammatory syndrome in an adult following Pfizer (MIS-V):

MIS-V in a 22yoF following Pfizer:

Multisystem inflammatory syndrome in a 12yo male following Pfizer:

Multisystem inflammatory Syndrome in a 12 year old boy after Pfizer:

MIS in a 12yoM following Pfizer:

3 cases of Multisystem Inflammatory Syndrome after Pfizer:

Multisystem Inflammation in a 20yoM following Pfizer:

MIS-A in a 21yoF following Moderna vaccination which was given 27 days after COVID infection:

MIS-A in a 37yoF 10 days post 2nd Moderna COVID vaccine and 1 month from COVID infection:

Multisystem inflammatory syndrome in children by covid-19 vaccination of adolescents in France:

Multisystem inflammatory syndrome in a COVID-19 vaccinated adolescent female with sickle cell disease:

Autoantibody release in children after COVID mRNA vaccination: A risk factor of multisystem inflammatory syndrome?

MIS in a 12yoM following Pfizer:

Multisystem inflammatory syndrome following COVID-19 vaccination: ignored and underdiagnosed:

Postmortem investigation of fatalities following vaccination with COVID-19 vaccines:

Autopsy findings and causality relationship between death and covid-19 vaccination: a systematic review:

MIS-C in a a male adolescent after his second dose of Pfizer:

Multisystem inflammatory syndrome in an adult following AstraZeneca:

Postvaccination MIS in an adult with no evidence of prior COVID-19 infection following AstraZeneca:

MIS-A in an adult woman 18 days following AstraZeneca vaccination:

MIS in a 16yoM following 1st dose mRNA vaccination:

MIS-A in  65yoM, Pfizer vaccine induced, with polyserositis detected by FDGMIS after J&J vaccine:

Fatal Multisystem inflammatory syndrome after 2nd dose of Pfizer:



Increased menstrual bleeding in 39,000 women after vaccination:

2 cases of adolescents with vulvar ulcers following Pfizer:

Vulvar aphthous ulcer after Pfizer in a 12yoF:

Vulvar aphthous ulcer in a 14yoF after Pfizer:

Vulvar aphthous ulcer in a 16yoF after Pfizer:

3 cases of acute vulvar aphthosis following Pfixer and AstraZeneca:

2 cases of adolescents with vulvar ulcers following Pfizer:

Acute genital ulceration after Pfizer (12 and 14yo) and a 29yo after Moderna:



SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro

SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: Evidence of PAMP-like properties – WITHOUT virus

The BNT162b2 mRNA vaccine against SARS-COV-2 reprograms both adaptive and innate immune response:

Does COVID-19 RNA based vaccines put at risk of immune-mediated diseases?

Cardiovascular, neurological, and pulmonary events following COVID-19 vaccination: an analysis of European data:

Comparative Safety of mRNA Vaccines with 433,672 US Veterans. Supplemental Material

Adverse events following covid-19 vaccination in South Korea from Feb to August 2021: a nationwide observational study:

Circulating extracellular vesicle microRNAs associated with adverse reactions, proinflammatory cytokine, and antibody production after covid-19 vaccination:

Adverse effects of COVID mRNA vaccines: the spike hypothesis:

Adverse drug reactions from Pfizer and AstraZeneca in Saudi Arabia:

International call for vaccine adverse reaction investigation:

Severe COVID-19 Vaccine (Pfizer) Side Effects are rare in older adults yet are linked with depressive symptoms:

Serious adverse events following immunization with AstraZeneca in India, a single center experience:

Adverse events with Pfizer among Korean healthcare workers:

Pathophysiological changes after vaccination:

New-onset panic disorder following Pfizer vaccination:

Psychosis associated with COVID-19 vaccination:

Characteristics and outcomes of adverse events after vaccination:

Symptomology following mRNA vaccination:

Pfizer and AstraZeneca post-vaccination side effects among Saudi vaccinees:

Prevalence of severe adverse events after AstraZeneca in Togo:

Immune mediate events associated with COVOD-19 disease, a review of Slovenia data:

Concerns for Pfizer vaccine failure to wildtype variants after Delta and vaccine induced enhanced illness, as demonstrated in a mice model:

Concerns about the lipid nanoparticle in the mRNA contributing to adverse reactions:

Covid-19 Vaccine Injuries — Preventing Inequities in Compensation

The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory:




This document is for informational purposes only.  React 19 does not diagnose medical conditions, offer treatment advice, treat illnesses, or prescribe medicine or drugs.  Any information contained on the Site is not a substitute for professional medical advice, diagnosis, and/or treatment. You should always seek the advice of your physician or other qualified health provider with any questions you may have regarding vaccine injury, COVID-19, or other topics discussed on the Site. It is strongly recommended that prior to acting upon information obtained from this document, you at all times first consult a physician or other qualified health care provider. React 19 does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on the Site. Reliance on any information available on this site is solely at your own risk.

Copyright React19 2022 – Contact us for permissions and terms of use.